ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer''s Disease

ID: 1520655
recent pressrelease next pressrelease

(Thomson Reuters ONE) -


TORONTO and CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) --

ProMIS Neurosciences, Inc., a company focused on discovery and development of
precision treatments for neurodegenerative diseases, today announced it has
designated PMN330, a monoclonal antibody (mAb) targeting toxic prion-like forms
of amyloid-beta oligomers (ABO), as its third lead product for development in
Alzheimer''s disease (AD).

"We previously validated PMN310 and PMN350, our two lead products for
development in Alzheimer''s disease based on their ability to selectively bind
prion-like forms of ABO, inhibiting both their propagation and neurotoxicity,"
stated Dr. Neil Cashman, ProMIS'' Chief Scientific Officer. "We have now achieved
a significant development milestone by demonstrating that PMN330, directed
against a different target on toxic ABO, also displays an optimal target product
profile in both in vitro and in vivo tests."

Injection of prion-like forms of ABO (also called toxic soluble oligomers) into
the brains of mice causes a neurological deficit that can be assessed in a
memory-behavior test called ''novel object recognition''.  Normal mice exposed to
an object remember the familiar object when re-exposed to it and spend more time
exploring a newly introduced object. In contrast, ABO-injected mice lose the
ability to discriminate between known and novel objects and spend equivalent
amounts of time exploring both. Results obtained in this assay showed that
administration of PMN330 to mice completely prevented the loss of short-term
memory formation caused by toxic oligomers. Furthermore, the observed cognitive
benefit of PMN330 was correlated with statistically significant preservation of
two synaptic biomarkers (SNAP25, PSD95), indicative of neuroprotection, and
reduction in a biomarker of neuroinflammation (TNFa) measured in hippocampal


brain homogenates. This neuroprotective effect of PMN330 was investigated at a
leading contract research organization specializing in neurodegenerative
diseases.

"These encouraging results underline the robust nature of our proprietary
discovery engine," commented Elliot Goldstein, MD, ProMIS'' President and CEO.
"We now have three validated development candidates for Alzheimer''s selectively
addressing a different target on toxic prion-like forms of ABO. The first of
these, PMN310, is on track for initiation of clinical trials in 2019."

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotech company
(trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in
Cambridge, Massachusetts. The mission of ProMIS is to discover and develop
precision medicine therapeutics for effective treatment of neurodegenerative
diseases, in particular Alzheimer''s disease and ALS.

ProMIS Neurosciences'' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS((TM)) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer''s disease and ALS. The company has also
developed two proprietary technologies to specifically identify very low levels
of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences
owns a portfolio of therapeutic and diagnostic patents relating to misfolded
SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic
against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company''s current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.


For further information please consult the Company''s website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843

David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: ProMIS Neurosciences via GlobeNewswire






More information:
http://www.pressreleasefinder.com/SABIC/SABICPR300/en/ http://www.pressreleasefinder.com/SABIC/SABICPR299/en/ http://www.BroadSoft.com https://www.addivant.com/ http://www.sofamania.com/collections/futon http://www.kesko.fi http://iconicbrandsusa.com htt



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: hugin
print pressrelease  send to a friend  

Date: 09/13/2017 - 07:30
Language: English
News-ID 1520655
Character count: 2094
Kontakt-Informationen:
Firma: ProMIS Neurosciences
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Toronto
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 317

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 8 020
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 56


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.